Teva (TEVA) Gets Buy Rating with Optimistic Outlook from Truist | IL:TEVA Stock News

Author's Avatar
May 27, 2025

Truist has commenced coverage of Teva (TEVA) with a Buy recommendation, setting a price target of $25. The analyst highlights Teva's strategic focus on enhancing its high-margin brands and bolstering its generics offerings as effective measures to mitigate risks associated with both revenue and margin profiles. The company's management is lauded for their effective execution of the "Pivot to Growth" strategy. Furthermore, the firm anticipates that Teva could achieve an operating margin of 30% by 2027, reflecting a promising financial trajectory.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.